This is a non-core endpoint: only basic statistics are computed.
Benign neoplasm: Orbit, unspecified
CD2_BENIGN_ORBIT_NOS_EXALLC
No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
|
1. Apply sex-specific ruleNone |
- |
2. Check conditionsNone |
|
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
- |
4. Check minimum number of eventsNone |
- |
5. Include endpointsNone |
- |
6. Filter based on genotype QC (FinnGen only)None |
- |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- D31
- Name in latin
- Neoplasma benignum orbitae non specificatum
Similar endpoints
↥List of similar endpoints to
Benign neoplasm: Orbit, unspecified
based on the number of shared cases.
Similar with more cases:
- Benign neoplasm: Orbit, unspecified
- Benign neoplasm of eye and adnexa
- Benign neoplasm of eye and adnexa
- Benign neoplasms
- Benign neoplasms
Similar with less cases:
Case counts by codes
↥FinnGen case counts by registry codes:
No upset plot: script not run.
No upset table: script not run.
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 217 | 144 | 73 |
| Unadjusted period prevalence (%) | 0.04 | 0.05 | 0.03 |
| Median age at first event (years) | 54.74 | 52.89 | 58.38 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 187
- Matched controls
- 1869
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D31.6
ICD-10 Finland
Benign neoplasm: Orbit, unspecified
+∞
210.2
160
*
CA1CG
NOMESCO Finland
Eye and orbita extensive MRI examination with high intensity magnet
168.2
39.4
40
*
CAA30
NOMESCO Finland
Biopsy of orbit
327.5
28.6
28
*
H05.2
ICD-10 Finland
Exophthalmic conditions
+∞
18.0
17
*
22405
ICD-8 Finland
Benign neoplasm of eye, Orbitae
+∞
16.9
16
*
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
7.3
15.3
38
63
CA1BG
NOMESCO Finland
Eye and orbita MRI examination with high intensity magnet
87.0
14.8
16
*
2241A
ICD-9 Finland
Benign neoplasm of eye, Orbit
+∞
14.8
14
*
CA1CM
NOMESCO Finland
Eye and orbita extensive MRI examination with 3 Tesla magnet
162.0
14.7
15
*
WF002
NOMESCO Finland
Radical radiotherapy
+∞
13.7
13
*
CAB00
NOMESCO Finland
Anterior orbitotomy with excision of lesion
+∞
13.7
13
*
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
13.6
13.5
23
19
H02AB02
ATC
dexamethasone; systemic
20.9
13.2
19
10
AAB00
NOMESCO Finland
Extirpation of intracranial lesion
26.9
11.3
15
6
Z01.0
ICD-10 Finland
Examination of eyes and vision
3.7
11.0
54
185
D48.7
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Other specified sites
116.1
10.5
11
*
CAB10
NOMESCO Finland
Lateral orbitotomy with excision of lesion
+∞
10.5
10
*
C83.80
ICD-10 Finland
B-cell lymphoma in marginal zone
+∞
10.5
10
*
D31.0
ICD-10 Finland
Benign neoplasm: Conjunctiva
25.0
10.4
14
6
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
42.5
10.1
12
*
WX408
NOMESCO Finland
General anesthesy, balanced
3.2
10.0
63
257
D32.02
ICD-10 Finland
Benign tumor of the meninges at the base of the brain
58.0
9.7
11
*
AAB10
NOMESCO Finland
Partial excision of intracranial lesion
31.8
9.5
12
*
WF003
NOMESCO Finland
Adjuvant radiotherapy
+∞
9.4
9
*
115
Kela drug reimbursment
Breast cancer
+∞
9.4
9
*
A04AA02
ATC
granisetron; systemic, transdermal
+∞
9.4
9
*
XCK00
NOMESCO Finland
Perimetry
5.0
9.0
29
66
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
4.7
8.8
30
73
JN4BD
NOMESCO Finland
Extensive body CT
6.4
8.6
22
38
CA1DG
NOMESCO Finland
Eye and orbita very extensive MRI examination with high intensity magnet
94.0
8.5
9
*
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
+∞
8.4
8
*
C69.60
ICD-10 Finland
Malignant tumor in orbit without histology
+∞
8.4
8
*
8090/3-C44.9
ICD-O-3
Basal cell carcinoma, NOS, of skin, NOS
+∞
8.4
8
*
C61
ICD-10 Finland
Malignant neoplasm of prostate
+∞
8.4
8
*
WX002
NOMESCO Finland
Sedation and analgesia
3.1
8.3
50
196
CK2S4
NOMESCO Finland
Plain photography of ocular fundus
5.0
8.3
26
58
AA1AD
NOMESCO Finland
CT of head and brain
2.7
7.9
61
280
D23.1
ICD-10 Finland
Benign neoplasm: Skin of eyelid, including canthus
6.7
7.8
19
31
S01XA20
ATC
artificial tears and other indifferent preparations; ophthalmic
2.4
7.6
95
562
C44.31
ICD-10 Finland
Basocellular carcinoma of the skin on another or unspecified part of the face
83.2
7.5
8
*
D36.1
ICD-10 Finland
Benign neoplasm: Peripheral nerves and autonomic nervous system
83.2
7.5
8
*
XCD10
NOMESCO Finland
Electrophysiological examination of eye
11.5
7.4
13
12
PJA12
NOMESCO Finland
Sentinel node biopsy
+∞
7.3
7
*
H05.9
ICD-10 Finland
Disorder of orbit, unspecified
+∞
7.3
7
*
130
Kela drug reimbursment
Malignant tumour
+∞
7.3
7
*
9699/3-C69.6
ICD-O-3
Marginal zone B-cell lymphoma, NOS, of orbit, NOS
+∞
7.3
7
*
ZXA05
NOMESCO Finland
Left side
2.7
7.3
58
270
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.3
6.7
90
543
9530/0-C70.0
ICD-O-3
Meningioma, NOS, of cerebral meninges
18.8
6.3
9
5
CBA10
NOMESCO Finland
Biopsy of eyelid
18.8
6.3
9
5
HAB40
NOMESCO Finland
Wedge excision of mammary gland
+∞
6.3
6
*
WF049
NOMESCO Finland
Radiotherapy of metastasis
+∞
6.3
6
*
L02BA01
ATC
tamoxifen; oral
+∞
6.3
6
*
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
6.3
6
*
8090/3-C44.3
ICD-O-3
Basal cell carcinoma, NOS, of skin of other and unspecified parts of face
+∞
6.3
6
*
8500/3-C50.9
ICD-O-3
Infiltrating duct carcinoma, NOS, of breast, NOS
+∞
6.3
6
*
116
Kela drug reimbursment
Prostate cancer
+∞
6.3
6
*
YA1AD
NOMESCO Finland
CT examination of head and neck for dose design of radiotherapy
+∞
6.3
6
*
XCK10
NOMESCO Finland
Photography of fundus of eye
3.3
6.2
31
106
CS494
NOMESCO Finland
Other visual field testing
8.1
6.2
13
17
CBB30
NOMESCO Finland
Excision of lesion of eyelid
8.1
6.2
13
17
D32.00
ICD-10 Finland
Benign tumor of the meninges on the outer surface of the cerebrum
13.1
6.1
10
8
WX110
NOMESCO Finland
Local anesthesy
2.2
6.1
130
946
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
10.5
6.1
11
11
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
144
917
2.70
10.80
7.8
5.9
4.2
4.2
e9/l
0.01
120
810
115
695
2.39
9.10
5.7
5.4
1.2
1.2
mmol/l
0.96
105
623
41
155
3.03
8.39
3.8
2.7
216.1
230.4
u/l
0.84
41
139
25
75
3.64
7.36
3.7
1.5
2.3
2.7
ug/l
0.31
18
53
117
761
2.17
7.22
7.2
5.9
1.2
1.2
mmol/l
0.44
103
660
142
1007
2.19
6.89
4.9
4.6
6.6
6.7
mmol/l
0.17
137
920
205
1762
3.96
5.80
16.0
12.0
22.0
21.8
mg/l
0.04
178
1328
162
1281
2.04
5.00
3.9
4.0
12.5
11.5
mm/h
0.44
152
1168
106
743
1.83
4.60
3.5
3.8
—
—
—
0
0
36
174
2.28
4.43
7.3
9.1
0.5
1.4
mmol/l
1.63
29
138
97
668
1.82
4.41
5.7
3.6
36.0
36.0
g/l
0.00
87
621
62
371
1.94
4.37
2.0
2.0
—
—
—
0
0
115
837
1.80
4.32
4.6
3.5
0.0
0.0
estimate
0.00
14
154
27
116
2.52
4.29
3.1
1.7
68.9
64.6
ml/min/173m2
0.24
12
46
157
1263
1.88
4.15
7.5
5.1
75.0
74.3
u/l
0.10
151
1161
20
75
2.84
4.12
9.7
8.8
24.8
24.6
mmol/l
0.15
20
68
115
849
1.75
4.01
6.1
4.9
0.0
0.0
estimate
0.00
14
152
116
860
1.75
3.98
4.7
3.6
0.0
0.0
estimate
0.00
14
152
112
824
1.74
3.93
6.5
3.7
10.9
11.0
umol/l
0.05
107
768
11
29
3.94
3.85
1.2
1.2
2.2
5.1
u/ml
—
6
14
12
34
3.68
3.82
2.2
2.7
—
—
—
0
0
59
362
1.87
3.80
2.4
1.8
1.4
1.1
mg/l
0.33
46
279
143
1136
1.76
3.74
6.4
4.5
—
5239.2
—
0
21
99
716
1.70
3.61
2.1
1.9
94.7
94.7
pmol/l
0.00
51
340
77
526
1.72
3.42
4.1
2.0
2.3
2.4
mmol/l
0.80
67
437
188
1650
2.04
3.26
13.8
10.7
83.3
81.1
ml/min/173m2
0.61
148
1308
63
412
1.75
3.24
1.5
1.5
23.6
21.0
nmol/l
0.58
58
355
47
283
1.84
3.18
3.7
2.3
0.5
1.2
e6/l
2.05
20
154
187
1647
1.98
3.07
5.5
4.8
1.7
1.9
mu/l
1.92
173
1508
9
21
4.42
3.03
1.6
1.2
—
—
—
0
0
201
1822
2.40
2.99
19.2
14.2
139.5
139.8
mmol/l
0.83
201
1766
38
224
1.84
2.74
2.7
3.1
0.8
0.8
mmol/l
0.09
33
204
160
1364
1.66
2.72
4.6
4.0
14.7
14.7
pmol/l
0.12
149
1240
6
10
6.13
2.71
1.7
2.1
—
—
—
0
0
66
457
1.64
2.70
3.5
2.7
0.4
0.5
e6/l
0.31
41
339
43
268
1.75
2.58
3.5
2.5
4.9
3.1
e6/l
0.25
16
138
80
588
1.57
2.54
3.8
2.8
—
—
—
0
0
204
1890
2.32
2.36
11.0
8.3
23.7
24.7
u/l
0.57
198
1817
19
92
2.17
2.35
9.8
8.3
0.8
0.7
%
0.14
19
92
19
93
2.14
2.29
9.8
8.3
1.2
1.5
%
0.96
19
93
7
18
3.98
2.27
1.3
1.0
—
—
—
0
0
179
1597
1.69
2.27
19.6
13.2
39.3
40.0
%
0.58
138
1171
39
248
1.70
2.18
1.9
1.8
—
—
—
0
0
29
169
1.83
2.17
2.1
1.7
—
—
—
0
0
166
1460
1.58
2.16
19.1
14.4
13.6
13.6
%
0.27
166
1431
210
1991
2.70
2.14
24.9
17.2
133.3
135.5
g/l
1.56
210
1954
29
170
1.81
2.13
2.1
1.7
—
—
—
0
0
9
31
2.98
2.10
1.3
1.2
—
—
—
0
0
9
31
2.98
2.10
1.3
1.2
—
—
—
0
0
18
90
2.09
2.07
2.6
2.1
10.0
15.1
nmol/l
1.48
13
84
19
98
2.03
2.02
1.9
1.5
—
—
—
0
0
19
98
2.03
2.02
1.5
1.4
—
—
—
0
0
10
39
2.64
1.95
1.6
1.2
—
—
—
0
0
32
202
1.69
1.84
3.1
2.3
22.1
23.7
%
0.27
27
172
5
12
4.24
1.83
1.2
1.0
—
—
—
0
0
8
29
2.82
1.81
1.3
1.1
—
—
—
0
0
10
41
2.51
1.78
3.5
1.3
73.3
35.7
mg/l
—
10
33
10
41
2.51
1.78
3.5
1.3
48.1
23.6
mg/l
—
10
33
83
654
1.44
1.77
4.1
3.7
20.8
37.2
ng/l
1.72
59
454
12
55
2.25
1.71
3.2
2.6
1150.9
8586.6
u/l
—
6
20
30
192
1.65
1.65
10.3
6.7
—
—
—
0
0
135
1172
1.40
1.60
2.8
2.9
36.3
43.3
u/l
0.99
125
1107
66
510
1.42
1.54
3.4
3.1
1194.9
1422.7
ng/l
0.25
53
417
15
79
1.97
1.53
5.5
5.0
24.8
25.2
mmol/l
0.26
15
79
48
352
1.47
1.47
4.9
4.1
22.6
207.4
ng/l
1.34
34
279
13
67
2.00
1.41
2.8
1.2
—
—
—
0
0
43
313
1.47
1.37
1.5
1.6
—
—
—
0
0
9
43
2.14
1.32
1.0
1.2
—
45.6
—
0
6
11
55
2.05
1.29
1.5
1.1
37.7
39.3
g/l
0.41
11
42
11
55
2.05
1.29
2.2
1.5
—
—
—
0
0
5
18
2.82
1.29
1.0
1.1
—
—
—
0
0
6
25
2.44
1.25
1.0
1.1
—
—
—
0
0
126
1109
1.32
1.23
3.3
3.1
—
—
—
0
0
180
1674
1.44
1.21
3.9
4.0
1.3
1.3
mmol/l
0.32
161
1542
187
1752
1.49
1.21
4.4
4.4
5.9
5.9
mmol/l
0.09
168
1600
187
1756
1.47
1.15
4.4
4.4
4.7
4.7
mmol/l
0.11
176
1633
53
414
1.37
1.15
2.9
2.0
2.8
2.9
mg/l
0.06
43
341
190
1791
1.49
1.13
5.2
4.9
2.8
2.7
mmol/l
0.11
178
1653
5
21
2.41
1.09
1.0
1.1
—
—
—
0
0
41
310
1.40
1.07
3.8
2.1
2.4
2.4
mmol/l
0.30
34
262
185
1742
1.42
1.03
4.4
4.4
1.5
1.5
mmol/l
0.65
170
1619
7
36
1.98
0.98
1.0
1.2
—
—
—
0
0
176
1653
1.34
0.92
5.8
5.8
39.3
39.7
mmol/mol
0.20
165
1549
8
43
1.89
0.88
1.1
1.2
—
1.0
—
0
8
15
96
1.60
0.87
3.4
3.5
5.2
5.2
kpa
0.02
15
90
8
44
1.85
0.87
1.3
1.2
—
—
—
0
0
88
767
1.25
0.83
3.4
2.6
96.8
98.7
ug/l
0.06
83
703
14
89
1.61
0.83
1.1
1.3
—
—
—
0
0
38
297
1.34
0.83
1.2
1.3
12.8
37.3
iu/ml
—
10
84
6
32
1.90
0.82
1.0
1.4
—
—
—
0
0
31
236
1.37
0.80
2.7
2.4
0.9
0.8
ug/l
0.34
19
144
77
665
1.24
0.78
5.3
3.6
—
—
—
0
0
7
38
1.87
0.74
1.0
1.2
—
—
—
0
0
40
321
1.30
0.73
1.7
1.6
1144.0
1181.4
nmol/l
0.09
31
243
26
198
1.36
0.68
2.1
1.9
—
—
—
0
0
7
43
1.65
0.67
1.0
1.1
—
—
—
0
0
28
217
1.33
0.66
4.3
4.4
30.6
32.3
%
0.39
19
143
36
291
1.28
0.63
1.3
1.3
1.2
11.5
u/ml
1.97
11
103
8
50
1.62
0.62
1.5
1.3
—
—
—
0
0
0
21
0.00
0.60
0.0
1.4
—
—
—
0
0
82
732
1.19
0.59
1.9
2.2
76.3
77.2
nmol/l
0.11
68
642
6
35
1.73
0.58
1.2
2.0
—
—
—
0
0
6
36
1.69
0.57
1.3
1.8
—
—
—
0
0
11
158
0.68
0.55
1.9
1.8
—
—
—
0
0
12
83
1.47
0.53
2.7
2.0
1.1
1.1
%
0.05
12
83
9
64
1.42
0.52
1.4
2.2
1075.9
317.2
ug/l
—
9
57
28
227
1.27
0.50
2.4
2.0
—
—
—
0
0
14
102
1.40
0.48
1.3
1.4
—
—
—
0
0
40
340
1.22
0.48
3.4
3.3
23.0
24.4
%
0.13
14
149
7
49
1.44
0.46
1.0
1.2
—
—
—
0
0
7
49
1.44
0.46
1.0
1.2
—
—
—
0
0
42
363
1.19
0.43
1.4
1.7
407.1
438.2
pmol/l
0.35
36
298
5
32
1.58
0.42
1.2
1.3
—
—
—
0
0
8
59
1.37
0.41
1.3
1.5
—
—
—
0
0
6
46
1.31
0.33
1.0
1.1
—
—
—
0
0
8
62
1.30
0.28
1.1
2.0
—
—
—
0
0
8
63
1.28
0.28
1.4
1.9
—
—
—
0
0
8
64
1.26
0.28
1.4
1.8
—
—
—
0
0
8
67
1.20
0.26
1.3
1.9
—
—
—
0
0
5
39
1.29
0.23
1.0
1.2
—
—
—
0
0
5
40
1.26
0.22
1.2
1.6
—
—
—
0
0
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.9
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
5
43
1.17
0.21
2.2
2.0
—
—
—
0
0
0
13
0.00
0.21
0.0
1.9
—
13.5
—
0
13
48
444
1.10
0.20
7.0
3.7
0.0
0.0
estimate
0.00
14
151
41
381
1.09
0.16
1.2
1.3
1.0
1.1
u/ml
—
7
95
6
77
0.77
0.16
6.0
1.9
1.3
3.8
mg/l
—
6
52
17
154
1.11
0.10
2.1
3.0
—
—
—
0
0
12
107
1.13
0.08
2.3
1.7
—
—
—
0
0
7
68
1.03
0.08
1.4
1.5
—
—
—
0
0
31
294
1.06
0.07
1.4
1.4
—
—
—
0
0
21
197
1.07
0.06
1.3
1.7
1.4
1.5
%
0.44
16
177
10
109
0.91
0.04
1.5
1.5
—
—
—
0
0
48
486
0.98
0.00
1.7
1.6
1.3
1.3
mmol/l
0.24
42
416
13
131
0.99
0.00
2.8
1.9
—
—
—
0
0
5
59
0.84
0.00
1.4
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
0.0
—
0
5
0
6
0.00
0.00
0.0
1.0
—
6.9
—
0
6
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
208.7
—
0
6
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
9
94
0.96
0.00
1.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.6
—
64.4
—
0
8
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.7
—
—
—
0
0
0
5
0.00
0.00
0.0
2.8
—
—
—
0
0
5
59
0.84
0.00
1.4
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
5
59
0.84
0.00
1.4
1.4
—
—
—
0
0
0
9
0.00
-0.00
0.0
2.4
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
2.4
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: CD2_BENIGN_ORBIT_NOS_EXALLC – Benign neoplasm: Orbit, unspecified
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).